INCY vs. JAZZ: Incyte vs. Jazz Pharmaceuticals Stock Comparison
How do Incyte (INCY) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Incyte (INCY) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.
| Profile Item | INCY | JAZZ |
|---|---|---|
| Name | Incyte Corp. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 24.39 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | November 4, 1993 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Total Return (1Y) | 14.06% | 84.44% |
| Total Return (3Y, Annualized) | 32.03% | 27.57% |
| Total Return (5Y, Annualized) | 12.69% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 33.19% | 38.74% |
| Beta (5Y) | 0.78 | 0.33 |
| Max Drawdown (5Y) | -40.50% | -42.03% |
| Avg. Volume (3M) | 1.58M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.29 | 2.07 |
| Sortino Ratio (1Y) | 0.46 | 4.14 |
Profitability
ROE (TTM)
Incyte (INCY) at 7.84% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for INCY.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Incyte (INCY) at 6.71% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Incyte (INCY) at 33.72% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| ROE (TTM) | 7.84% | 5.05% |
| ROA (TTM) | 17.78% | 6.92% |
| Net Margin (TTM) | 6.71% | 4.37% |
| Operating Margin (TTM) | 33.72% | 30.17% |
| Gross Margin (TTM) | 56.02% | 91.10% |
Growth
Revenue Growth
Both Incyte (INCY) at 21.22% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% delivers above-range EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% falls into the bottom quartile — a wide split in earnings momentum.
Growth Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 21.22% | 4.88% |
| Revenue Growth (3Y CAGR) | 14.84% | 5.26% |
| EPS Growth (YoY) | 4,173.33% | -167.51% |
| EPS Growth (3Y CAGR) | 61.56% | -- |
Financial Strength
Current Ratio (MRQ)
Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 3.84 | 1.82 |
| Debt / Equity (MRQ) | 0.01 | 1.35 |
| Net Debt / EBITDA | -1.88 | 1.39 |
Dividends
Dividend Yield (TTM)
Neither Incyte (INCY) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Incyte (INCY) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Incyte (INCY) at 61.05 and Jazz Pharmaceuticals (JAZZ) at 69.46 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Incyte (INCY) at 4.06 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Incyte (INCY) at 4.33 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INCY | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 61.05 | 69.46 |
| P/S Ratio (TTM) | 4.06 | 3.19 |
| P/B Ratio (MRQ) | 4.33 | 3.59 |
| Free Cash Flow Yield (TTM) | 5.28% | 11.16% |